
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Medite Cancer Diagnostics Inc (CE) | USOTC:MDIT | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.000001 | 0.00 | 00:00:00 |
☒
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
|
|
For the quarterly period ended June 30, 2018
|
|
|
|
|
☐
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
|
|
For the transition period from
to
.
|
Delaware
|
36-4296006
|
(State or other jurisdiction of
|
(I.R.S. Employer
|
incorporation or organization)
|
Identification No.)
|
|
|
10524 Moss Park Rd. Ste-204-357, Orlando, FL
|
32832
|
(Address of principal executive offices)
|
(Zip Code)
|
Title of each class
|
Name of each exchange on which registered
|
None
|
Not
Applicable
|
Large
Accelerated Filer
☐
|
Accelerated
Filer
☐
|
Non-Accelerated
Filer
☐
|
Smaller
Reporting Company
☒
|
|
Emerging
growth company
☐
|
|
|
Page
|
|
|
|
|
|
||
|
|
|
|
|
|
1
|
|
||
|
|
|
|
|
|
|
1
|
|
|
|
|
|
|
|
|
|
2
|
|
|
|
|
|
|
|
|
|
4
|
|
|
|
|
|
|
|
|
|
5
|
|
|
|
|
|
|
|
|
15
|
|
||
|
|
|
|
|
|
20
|
|
||
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
21
|
|
||
|
|
|
|
|
|
21
|
|
||
|
|
|
|
|
|
21
|
|
||
|
|
|
|
|
|
22
|
|
||
|
|
|
|
|
|
23
|
|
|
June
30, 2018
|
December
31,
|
|
(unaudited)
|
2017
|
Assets
|
|
|
Current
Assets:
|
|
|
Cash
|
$
47
|
$
73
|
Restricted
cash
|
35
|
417
|
Accounts
receivable, net of allowance for doubtful accounts of $452 and
$439
|
910
|
453
|
Inventories
|
2,828
|
2,403
|
Prepaid
expenses and other current assets
|
321
|
118
|
Total
current assets
|
4,141
|
3,464
|
|
|
|
Property
and equipment, net
|
1,608
|
1,778
|
In-process
research and development
|
4,620
|
4,620
|
Trademarks,
trade names
|
1,240
|
1,240
|
Goodwill
|
4,658
|
4,658
|
Other
assets
|
338
|
196
|
Total
assets
|
$
16,605
|
$
15,956
|
|
|
|
Liabilities
and Stockholders’ Equity
|
|
|
Current
Liabilities:
|
|
|
Accounts
payable and accrued expenses
|
$
3,127
|
$
3,252
|
Current
portion of long-term debt
|
50
|
50
|
Notes
due to employees, current portion
|
326
|
326
|
Advances
– related party
|
119
|
154
|
Total
current liabilities
|
3,622
|
3,782
|
|
|
|
Long-term
debt, net of current portion and debt discounts
|
5,394
|
4,869
|
Notes
due to employees, net of current portion
|
-
|
45
|
Deferred
tax liability
|
1,485
|
1,485
|
Total
liabilities
|
10,501
|
10,181
|
|
|
|
Commitments
and contingencies
|
|
|
|
|
|
Stockholders’
Equity:
|
|
|
Preferred
stock, $0.001 par value; 10,000,000 shares authorized; 198,355
shares issued and outstanding (liquidation value of all classes of
preferred stock $2,670 and $2,624 as of June 30, 2018 and December
31, 2017, respectively)
|
962
|
962
|
Common
stock, $0.001 par value; 100,000,000 shares authorized, 60,706,201
and 28,906,081 shares issued and outstanding as of June 30, 2018
and December 31, 2017, respectively
|
61
|
29
|
Additional
paid-in capital
|
16,216
|
13,750
|
Treasury
stock
|
(327
)
|
(327
)
|
Accumulated
other comprehensive loss
|
(648
)
|
(444
)
|
Accumulated
deficit
|
(10,160
)
|
(8,195
)
|
Total
stockholders’ equity
|
6,104
|
5,775
|
Total
liabilities and stockholders’ equity
|
$
16,605
|
$
15,956
|
|
Three
Months Ended June 30,
|
|
|
2018
|
2017
|
|
|
|
Net
sales
|
$
2,275
|
$
1,277
|
Cost
of revenues
|
1,215
|
1,228
|
Gross
profit
|
1,060
|
49
|
|
|
|
Operating
expenses:
|
|
|
Depreciation
and amortization expense
|
68
|
54
|
Research
and development
|
258
|
329
|
Selling,
general and administrative
|
762
|
1,228
|
Total
operating expenses
|
1,088
|
1,611
|
Operating
loss
|
(28
)
|
(1,562
)
|
|
|
|
Other
(income) expense:
|
|
|
Interest
expense, net
|
540
|
67
|
Other income,
net
|
(9
)
|
(8
)
|
Total
other expense, net
|
531
|
59
|
Loss
before income taxes
|
(559
)
|
(1,621
)
|
|
|
|
Provision
for income taxes
|
4
|
4
|
Net
loss
|
(563
)
|
(1,625
)
|
|
|
|
Preferred
dividend
|
(23
)
|
(23
)
|
Net
loss available to common stockholders
|
$
(586
)
|
$
(1,648
)
|
|
|
|
Loss
per share
|
|
|
Net
loss available to common stockholders
|
$
(586
)
|
$
(1,648
)
|
Basic
and diluted loss per share
|
$
(0.01
)
|
$
(0.06
)
|
Weighted
average basic and diluted shares outstanding
|
55,465,112
|
25,866,163
|
|
|
|
Condensed
consolidated statements of comprehensive loss
|
|
|
Net
loss
|
$
(563
)
|
$
(1,625
)
|
Other
comprehensive income (loss)
|
|
|
Foreign
currency translation adjustments
|
(279
)
|
212
|
Comprehensive
loss
|
$
(842
)
|
$
(1,413
)
|
|
Six
Months Ended June 30,
|
|
|
2018
|
2017
|
|
|
|
Net
sales
|
$
3,780
|
$
3,168
|
Cost
of revenues
|
2,385
|
2,439
|
Gross
profit
|
1,395
|
729
|
|
|
|
Operating
expenses:
|
|
|
Depreciation
and amortization expense
|
139
|
103
|
Research
and development
|
563
|
754
|
Selling,
general and administrative
|
1,681
|
2,010
|
Total
operating expenses
|
2,383
|
2,867
|
Operating
loss
|
(988
)
|
(2,138
)
|
|
|
|
Other
(income) expense:
|
|
|
Interest
expense, net
|
987
|
260
|
Loss
on extinguishment of notes due to employees
|
-
|
158
|
Other (income)
expense, net
|
(14
)
|
20
|
Total
other expense, net
|
973
|
438
|
Loss
before income taxes
|
(1,961
)
|
(2,576
)
|
|
|
|
Provision
for income taxes
|
4
|
4
|
Net
loss
|
(1,965
)
|
(2,580
)
|
|
|
|
Preferred
dividend
|
(46
)
|
(46
)
|
Net
loss available to common stockholders
|
$
(2,011
)
|
$
(2,626
)
|
|
|
|
Loss
per share
|
|
|
Net
loss available to common stockholders
|
$
(2,011
)
|
$
(2,626
)
|
Basic
and diluted loss per share
|
$
(0.04
)
|
$
(0.11
)
|
Weighted
average basic and diluted shares outstanding
|
47,399,995
|
24,411,435
|
|
|
|
Condensed
consolidated statements of comprehensive loss
|
|
|
Net
loss
|
$
(1,965
)
|
$
(2,580
)
|
Other
comprehensive income (loss)
|
|
|
Foreign
currency translation adjustments
|
(204
)
|
159
|
Comprehensive
loss
|
$
(2,169
)
|
$
(2,421
)
|
|
Six
Months Ended June 30,
|
|
|
2018
|
2017
|
Cash
flows from operating activities:
|
|
|
Net
loss
|
$
(1,965
)
|
$
(2,580
)
|
Adjustments
to reconcile net loss to cash used in operating
activities
|
|
|
Depreciation
and amortization
|
139
|
103
|
Amortization
of debt discounts and debt issuance costs
|
413
|
-
|
Provision
for doubtful accounts
|
-
|
62
|
Stock-based
compensation
|
85
|
63
|
Estimated
fair value of warrants issued in connection with secured promissory
notes
|
-
|
162
|
Loss
on extinguishment of notes due to employees
|
-
|
158
|
Amortization
of shares issued for prepaid consulting services
|
-
|
6
|
Changes
in operating assets and liabilities:
|
|
|
Accounts
receivable
|
(482
)
|
302
|
Inventories
|
(502
)
|
114
|
Prepaid
expenses and other assets
|
(366
)
|
(95
)
|
Accounts
payable and accrued expenses
|
22
|
313
|
Net
cash used in operating activities
|
(2,656
)
|
(1,392
)
|
|
|
|
Cash
flows from investing activities:
|
|
|
Purchases
of equipment
|
(4
)
|
(27
)
|
Net
cash used in investing activities
|
(4
)
|
(27
)
|
|
|
|
Cash
flows from financing activities:
|
|
|
Net
repayments on lines of credit
|
-
|
(24
)
|
Repayment
of secured promissory notes
|
-
|
(167
)
|
Repayment
of notes due to employees
|
(45
)
|
(155
)
|
Proceeds
from convertible debt
|
2,394
|
-
|
Repayments
on related party advances
|
(34
)
|
-
|
Proceeds
from common stock subscribed
|
-
|
25
|
Proceeds
from sale of common stock, net of issuance costs
|
-
|
2,000
|
Net
cash provided by financing activities
|
2,315
|
1,679
|
|
|
|
Effect
of exchange rates on cash
|
(63
)
|
42
|
Net
change in cash and restricted cash
|
(408
)
|
302
|
Cash
and restricted cash at beginning of period
|
490
|
108
|
Cash
and restricted cash at end of the period
|
$
82
|
$
410
|
|
|
|
Supplemental
disclosure of cash flow information:
|
|
|
Cash
paid for interest
|
$
246
|
$
97
|
Cash
paid for income taxes
|
$
-
|
$
24
|
|
|
|
Reconciliation
of cash and restricted cash at end of period:
|
|
|
Cash
|
$
47
|
$
410
|
Restricted
cash
|
35
|
-
|
|
|
|
Supplemental
schedule of non-cash investing and financing
activities:
|
|
|
Issuance
of common stock for services
|
$
-
|
$
25
|
Issuance
of common stock subscribed
|
$
-
|
$
25
|
Conversion
of secured promissory note plus accrued interest into common
stock
|
$
-
|
$
58
|
Fair
value of common stock issued with debt recorded as a debt
discount
|
$
2,385
|
$
-
|
Accrued
liabilities exchanged for convertible note payable
|
$
130
|
$
-
|
Estimated
fair value of warrants recorded as debt discount
|
$
28
|
$
-
|
Note
3.
Inventories
|
|
|
|
|
|
|
|
The following is a summary of the components of inventories (in
thousands):
|
|
June
30,
|
December
31,
|
|
2018
|
2017
|
|
(Unaudited)
|
|
|
|
|
Raw
materials
|
$
1,596
|
$
1,220
|
Work
in process
|
40
|
44
|
Finished
goods
|
1,192
|
1,139
|
|
$
2,828
|
$
2,403
|
|
June
30,
|
December
31,
|
|
2018
|
2017
|
|
(Unaudited)
|
|
|
|
|
Secured
promissory note
|
$
50
|
$
50
|
Subordinated
convertible notes payable
|
1,085
|
932
|
GPB
Debt Holdings II, LLC Convertible note payable
|
5,356
|
5,356
|
2018
convertible notes payable
|
2,385
|
-
|
Total
|
8,876
|
6,338
|
|
|
|
Discount
on convertible notes payable
|
(3,432
)
|
(1,419
)
|
Less
current portion of long-term debt
|
(50
)
|
(50
)
|
Long-term
debt
|
$
5,394
|
$
4,869
|
|
United
States
|
Germany
|
Total
|
|||
|
June
30,
2018 |
December
31,
2017 |
June
30,
2018 |
December
31,
2017 |
June
30,
2018 |
December
31,
2017 |
Total
assets
|
$
11,142
|
$
11,179
|
$
5,463
|
$
4,777
|
$
16,605
|
$
15,956
|
Property
and equipment, net
|
88
|
108
|
1,520
|
1,670
|
1,608
|
1,778
|
Intangible
assets
|
10,518
|
10,518
|
-
|
-
|
10,518
|
10,518
|
|
United
States
|
Germany
|
Total
|
|||
For
the three months ended
|
June
30,
|
June
30,
|
June
30,
|
June
30,
|
June
30,
|
June
30,
|
|
2018
|
2017
|
2018
|
2017
|
2018
|
2017
|
Revenues:
|
|
|
|
|
|
|
Histology
Equipment
|
$
82
|
$
38
|
$
1,421
|
$
225
|
$
1,503
|
$
263
|
Histology
Consumables
|
81
|
136
|
552
|
667
|
633
|
803
|
Cytology
Consumables
|
-
|
-
|
139
|
211
|
139
|
211
|
|
|
|
|
|
|
|
Total
Revenues
|
$
163
|
$
174
|
$
2,112
|
$
1,103
|
$
2,275
|
$
1,277
|
|
|
|
|
|
|
|
Net
Income (Loss)
|
$
(1,006
)
|
$
(667
)
|
$
443
|
$
(958
)
|
$
(563
)
|
$
(1,625
)
|
|
United
States
|
Germany
|
Total
|
|||
For
the six months ended
|
June
30,
2018
|
June
30,
2017
|
June
30,
2018
|
June
30,
2017
|
June
30,
2018
|
June
30,
2017
|
Revenues:
|
|
|
|
|
|
|
Histology
Equipment
|
$
110
|
$
184
|
$
2,109
|
$
993
|
$
2,219
|
$
1,177
|
Histology
Consumables
|
173
|
240
|
1,140
|
1,240
|
1,313
|
1,480
|
Cytology
Consumables
|
-
|
-
|
248
|
511
|
248
|
511
|
|
|
|
|
|
|
|
Total
Revenues
|
$
283
|
$
424
|
$
3,497
|
$
2,744
|
$
3,780
|
$
3,168
|
|
|
|
|
|
|
|
Net
Loss
|
$
(1,955
)
|
$
(1,237
)
|
$
(10
)
|
$
(1,343
)
|
$
(1,965
)
|
$
(2,580
)
|
|
|
|
|
|
|
|
Definition:
|
Histology
- Cancer diagnostics based on the structures of cells in
tissues
|
|
Cytology
- Cancer screening and diagnostics based on the structures of
individual cells
|
Exhibit
|
|
|
Number
|
|
Description
|
|
|
|
|
|
|
|
Section
302 certification by the principal executive officer pursuant to
Rules 13a-14(a) or 15d-14(a) of the Securities Exchange Act of
1934, as adopted pursuant to Section 302 of the Sarbanes Oxley Act
of 2002.
|
|
|
|
|
|
Section
302 certification by the chief financial officer pursuant to Rules
13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as
adopted pursuant to Section 302 of the Sarbanes Oxley Act of
2002.
|
|
|
|
|
|
Section
906 certification by the principal executive pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of the Sarbanes
Oxley Act of 2002.
|
|
|
|
|
|
Section
906 certification by the chief financial officer pursuant to 18
U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes Oxley Act of 2002.
|
|
|
|
|
101.INS
|
|
XBRL
Instance
|
|
|
|
101.SCH
|
|
XBRL
Taxonomy Extension Schema
|
|
|
|
101.CAL
|
|
XBRL
Taxonomy Extension Calculation
|
|
|
|
101.DEF
|
|
XBRL
Taxonomy Extension Definition
|
|
|
|
101.LAB
|
|
XBRL
Taxonomy Extension Labels
|
|
|
|
101.PRE
|
|
XBRL
Taxonomy Extension Presentation
|
|
MEDITE
Cancer Diagnostics, Inc.
|
|
|
Date: August
10, 2018
|
/s/ Stephen Von
Rump
|
|
Stephen
Von Rump
|
|
Chief
Executive Officer
|
|
|
Date:
August 10, 2018
|
/s/ Stephen Von
Rump
|
|
Stephen
Von Rump
|
|
Chief
Financial Officer
|
1 Year Medite Cancer Diagnostics (CE) Chart |
1 Month Medite Cancer Diagnostics (CE) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions